Spiorad Medical

Executive Summary

Spiorad Medical is an Irish medical device company developing a novel closure device for large-bore femoral artery access sites (12F-24F). These access sites are used in complex interventional procedures such as transcatheter aortic valve replacement (TAVR) and endovascular aneurysm repair (EVAR), where effective hemostasis remains a significant challenge. Current closure options often fail with larger sheaths, leading to complications like bleeding, pseudoaneurysm, and prolonged recovery. Spiorad's solution aims to provide interventionalists with an easy-to-use, reliable closure method that improves clinical outcomes and reduces time to hemostasis and ambulation. Founded in 2018 and based in Galway, the company has assembled expertise in vascular access and closure technologies. The device is designed to address a clear unmet need in a growing market driven by the increasing adoption of minimally invasive structural heart and vascular interventions. Spiorad is positioned to compete with established players such as Abbott's Perclose and Medtronic's ProGlide, but offers a differentiated approach for large access sites. The company is progressing through preclinical and early clinical stages. The management team likely has deep experience in medical device development and regulatory pathways. Spiorad's success depends on demonstrating safety and efficacy in clinical trials, achieving regulatory clearance (CE Mark for EU, and eventually FDA approval for US), and securing distribution partnerships. The global market for vascular closure devices is estimated at over $1 billion and growing, providing a substantial commercial opportunity. Key near-term catalysts include the initiation of a pivotal clinical trial, submission for CE Mark, and potential strategic collaborations or funding rounds. With a strong value proposition and a clear pathway, Spiorad Medical is well-positioned to capture significant share in the large-bore closure market.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Pivotal Clinical Trial for CE Mark Approval70% success
• Q3 2027Submission of CE Mark Application60% success
• Q2 2026Series A or B Funding Round to Support Clinical Development80% success